```
=> d his

     (FILE 'HOME' ENTERED AT 11:11:11 ON 17 AUG 2006)

     FILE 'REGISTRY' ENTERED AT 11:11:38 ON 17 AUG 2006
L1            1 S L-HPC/CN

     FILE 'CAPLUS' ENTERED AT 11:13:05 ON 17 AUG 2006

     FILE 'REGISTRY' ENTERED AT 11:14:17 ON 17 AUG 2006
L2            1 S L-HPC

     FILE 'CAPLUS' ENTERED AT 11:15:15 ON 17 AUG 2006
L3         9718 S L2 OR L-HPC OR L-HPC(W)11 OR L-HPC(W)LH OR  HYDROPROPYL(W)CEL

     FILE 'REGISTRY' ENTERED AT 11:17:07 ON 17 AUG 2006
                E FEXOFENADINE/CN
L4            4 S E3-E6

     FILE 'CAPLUS' ENTERED AT 11:18:12 ON 17 AUG 2006
L5          624 S L4
L6            0 S L5(L)L3

     FILE 'USPATFULL, USPAT2' ENTERED AT 11:18:49 ON 17 AUG 2006
L7            0 S L6

     FILE 'CAPLUS' ENTERED AT 11:19:19 ON 17 AUG 2006
L8          136 S L-HPC OR L-HPC(W)11 OR L-HPC(W)LH OR  (HYDROPROPYL(W)CELLULOS
L9           95 S L8 NOT PY>=2003
L10          22 S L8(L)LACTOSE

     FILE 'REGISTRY' ENTERED AT 11:41:09 ON 17 AUG 2006
                E BALOFLOXACIN/CN
L11           1 S E3
```

```
=> s e3-e6
             1 FEXOFENADINE/CN
             1 "FEXOFENADINE HYDROCHLORIDE"/CN
             1 "FEXOFENADINE METHYL ESTER"/CN
             1 FEXOFENADINE-D6/CN
L4           4 (FEXOFENADINE/CN OR "FEXOFENADINE HYDROCHLORIDE"/CN OR "FEXOFENA
               DINE METHYL ESTER"/CN OR FEXOFENADINE-D6/CN)

=> d rn str cn

L4   ANSWER 1 OF 4  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   548783-71-7  REGISTRY
```




```
CN   Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-
     piperidinyl]butyl]-α,α-di(methyl-d3)- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   Fexofenadine-d6
```

L9 ANSWER 15 OF 95 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:822713 CAPLUS
DOCUMENT NUMBER: 133:363899
TITLE: Low-substituted hydroxypropyl cellulose
INVENTOR(S): Obara, Sakae
PATENT ASSIGNEE(S): Shin-Etsu Chemical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1054019	A1	20001122	EP 2000-304109	20000516
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001031701	A2	20010206	JP 2000-144253	20000517
US 6380381	B1	20020430	US 2000-573369	20000517
CN 1275405	A	20001206	CN 2000-118297	20000518
PRIORITY APPLN. INFO.:			JP 1999-136787 A	19990518

AB Low-substituted hydroxypropyl cellulose exhibits good granulation characteristics and tablet properties. Low-substituted hydroxypropyl cellulose has a hydroxypropoxyl content 5-16.0% and an apparent average d.p. 350-700. L-HPC (preparation given) having hydroxypropoxyl content 11%, apparent average d.p. 530, and bulk d. 0.55 g/mL, showed good granulation and tablet hardness 5.2 kg; vs. poor and 1.5, resp., for L-HPC having apparent average d.p. 810, bulk d. 0.51 g/mL.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 95 OF 95 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1978:110550 CAPLUS
DOCUMENT NUMBER: 88:110550
TITLE: Sugar coating of solid pharmaceutical preparations
INVENTOR(S): Maekawa, Hideyuki; Noda, Kinsaburo; Hoshi, Noboru
PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan; Shin-Etsu Chemical Industry Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 52151717	A2	19771216	JP 1976-67918	19760609
JP 55035366	B4	19800912		
DE 2725390	A1	19771222	DE 1977-2725390	19770604
DE 2725390	C2	19880505		
US 4176175	A	19791127	US 1977-803853	19770606
CH 630258	A	19820615	CH 1977-6923	19770606
AT 7704070	A	19790415	AT 1977-4070	19770608
AT 353416	B	19791112		
FR 2354094	A1	19780106	FR 1977-17658	19770609
FR 2354094	B1	19810529		
GB 1560854	A	19800213	GB 1977-24144	19770609

PRIORITY APPLN. INFO.: JP 1976-67918 A 19760609

AB Solid drug prepns. (tablets, granules, pills) are subcoated with sugars containing hydroxypropyl cellulose [9004-64-2] (L-HPC; 4-16% hydroxypropylates) to improve the disintegration time. Thus, tablets containing vitamins were subcoated with a syrup composition containing sugar, H2O, gelatin and gum arabic and a dusting powder containing talc and L-HPC. The disintegration time of the coated tablets immediately after preparation was 15 min compared with 27 min for those coated by conventional methods.

L10 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:186324 CAPLUS
DOCUMENT NUMBER: 126:176925
TITLE: Balofloxacin preparations containing low-substituted hydroxypropyl cellulose or crospovidone
INVENTOR(S): Suzuki, Nobuyuki; Myazaki, Masato; Matsuda, Katsuya
PATENT ASSIGNEE(S): Chugai Pharmaceutical Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09002953	A2	19970107	JP 1995-184583	19950616
PRIORITY APPLN. INFO.:			JP 1995-184583	19950616

AB Balofloxacin (I) prepns. containing low-substituted hydroxypropyl cellulose and/or crospovidone are claimed. The prepns. may addnl. contain excipients. The prepns. of I show relatively fast dissoln. under acidic to neutral conditions and the bioavailability is less dependent on gastrointestinal pH. A granule (143.55 g) obtained from I 150, L -HPC LH 31 5.6, lactose 42, crystalline cellulose 15, and 5% HPC-L aqueous solution 54 g was mixed with L-HPC LH 11 3.75, Lubriwax 101 (hydrogenated oil) 1.5, and Ca stearate 1,2 g and the mixture was made into tablets (100 mg I/tablet; 5% L -HPC/tablet). The tablet showed time for 75% dissoln. 4-5 min at pH 1.2, 4-6 min at pH 4.0, and 5-6 min at pH 6.5.

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:136558 CAPLUS
DOCUMENT NUMBER: 142:225793
TITLE: A process for preparing fexofenadine composition
INVENTOR(S): Nandi, Indranil; Patel, Ashish Anilbhai; Sadatrezaei, Mohsen; Davila, Pablo; Khanapure, Virendra Maheshappa; Durugkar, Surendra Wasudeorao
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013987	A1	20050217	WO 2004-EP8600	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005065183	A1	20050324	US 2003-631874	20030731
AU 2004262914	A1	20050217	AU 2004-262914	20040730
EP 1651218	A1	20060503	EP 2004-763678	20040730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.: US 2003-631874 A 20030731
WO 2004-EP8600 W 20040730

AB A pharmaceutical composition comprising fexofenadine or a pharmaceutically acceptable salt thereof, lactose, a low-substituted hydroxypropyl cellulose and optionally other excipients is disclosed. The fexofenadine compns. of the invention exhibit improved bioavailability as expressed as Cmax, the maximum amount of active ingredient found in the plasma, or as AUC, the area under the plasma concentration time curve. For example, a fexofenadine tablet composition was prepared by wet granulation of a powder blend containing fexofenadine-HCl 180 g, lactose 348 g, and hydroxypropyl cellulose 30 g. Wet granules were dried and then passed through 20 mesh, blended with crospovidone 36 g, and then with magnesium stearate 6 g. The lubricated granules were then compressed into tablets. The compressed tablets were optionally film coated with a composition containing HPMC 70%, TiO2 19.2%, propylene glycol 10%, yellow iron oxide 0.5%, and red iron oxide 0.3% to a total weight of 618 mg.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:136558 CAPLUS
DOCUMENT NUMBER: 142:225793
TITLE: A process for preparing fexofenadine composition
INVENTOR(S): Nandi, Indranil; Patel, Ashish Anilbhai; Sadatrezaei, Mohsen; Davila, Pablo; Khanapure, Virendra Maheshappa; Durugkar, Surendra Wasudeorao
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013987	A1	20050217	WO 2004-EP8600	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005065183	A1	20050324	US 2003-631874	20030731
AU 2004262914	A1	20050217	AU 2004-262914	20040730
EP 1651218	A1	20060503	EP 2004-763678	20040730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.: US 2003-631874 A 20030731
WO 2004-EP8600 W 20040730

AB A pharmaceutical composition comprising fexofenadine or a pharmaceutically acceptable salt thereof, lactose, a low -substituted hydroxypropyl cellulose and optionally other excipients is disclosed. The fexofenadine compns. of the invention exhibit improved bioavailability as expressed as Cmax, the maximum amount of active ingredient found in the plasma, or as AUC, the area under the plasma concentration time curve. For example, a fexofenadine tablet composition was prepared by wet granulation of a powder blend containing fexofenadine-HCl 180 g, lactose 348 g, and hydroxypropyl cellulose 30 g. Wet granules were dried and then passed through 20 mesh, blended with crospovidone 36 g, and then with magnesium stearate 6 g. The lubricated granules were then compressed into tablets. The compressed tablets were optionally film coated with a composition containing HPMC 70%, TiO2 19.2%, propylene glycol 10%, yellow iron oxide 0.5%, and red iron oxide 0.3% to a total weight of 618 mg.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:136558 CAPLUS
DOCUMENT NUMBER: 142:225793
TITLE: A process for preparing fexofenadine composition
INVENTOR(S): Nandi, Indranil; Patel, Ashish Anilbhai; Sadatrezaei, Mohsen; Davila, Pablo; Khanapure, Virendra Maheshappa; Durugkar, Surendra Wasudeorao
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013987	A1	20050217	WO 2004-EP8600	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005065183	A1	20050324	US 2003-631874	20030731
AU 2004262914	A1	20050217	AU 2004-262914	20040730
EP 1651218	A1	20060503	EP 2004-763678	20040730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.: US 2003-631874 A 20030731
WO 2004-EP8600 W 20040730

AB A pharmaceutical composition comprising fexofenadine or a pharmaceutically acceptable salt thereof, lactose, a low-substituted hydroxypropyl cellulose and optionally other excipients is disclosed. The fexofenadine compns. of the invention exhibit improved bioavailability as expressed as Cmax, the maximum amount of active ingredient found in the plasma, or as AUC, the area under the plasma concentration time curve. For example, a fexofenadine tablet composition was prepared by wet granulation of a powder blend containing fexofenadine-HCl 180 g, lactose 348 g, and hydroxypropyl cellulose 30 g. Wet granules were dried and then passed through 20 mesh, blended with crospovidone 36 g, and then with magnesium stearate 6 g. The lubricated granules were then compressed into tablets. The compressed tablets were optionally film coated with a composition containing HPMC 70%, TiO2 19.2%, propylene glycol 10%, yellow iron oxide 0.5%, and red iron oxide 0.3% to a total weight of 618 mg.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:611930 CAPLUS
DOCUMENT NUMBER: 143:139149
TITLE: Oral pharmaceutical compositions
INVENTOR(S): Mungre, Ashish Prabhakar; Nabar, Manisha Saiprasad
PATENT ASSIGNEE(S): Sun Pharmaceutical Industries Limited, India
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005062722	A2	20050714	WO 2004-IN362	20041122
WO 2005062722	A3	20050922		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IN 2003-MU1204 A 20031121

AB The present invention provides an immediate release oral pharmaceutical composition comprising fexofenadine or its salts, a dissoln. enhancing amount of a thermomelting binding agent and excipients. Tablets contained fexofenadine-HCl 30.0, lactose 50.0, Prosolv SMCC-90 17.5, SLS 1.0, colloidal silica 0.5, and Mg stearate 1.0%.

L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:430016 CAPLUS
DOCUMENT NUMBER: 143:109441
TITLE: The efficacy of short-term administration of 3 antihistamines vs. placebo under natural exposure to Japanese cedar pollen
AUTHOR(S): Hyo, Sawako; Fujieda, Shigeharu; Kawada, Ryo; Kitazawa, Shikifumi; Takenaka, Hiroshi
CORPORATE SOURCE: Department of Otorhinolaryngology, Osaka Medical College, Osaka, Japan
SOURCE: Annals of Allergy, Asthma, & Immunology (2005), 94(4), 457-464
CODEN: ALAIF6; ISSN: 1081-1206
PUBLISHER: American College of Allergy, Asthma, & Immunology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Japanese cedar pollinosis, a common disease with morbidity of approx. 20% in the Japanese population, is characterized by subjectively irritating symptoms during an annual 3-mo period. The aim was to investigate the effectiveness of cetirizine hydrochloride, loratadine, and fexofenadine hydrochloride in reducing pollinosis symptoms induced while walking in a park during the pollen season. A randomized, double-masked, placebo-controlled trial was conducted in 113 individuals with Japanese cedar pollinosis during 2 days in Mar. 2003 in Osaka Expo Park, Osaka, Japan. Participants (aged 20-57 years) were divided into 4 groups according to treatment assignment: cetirizine hydrochloride, 10 mg/d; fexofenadine hydrochloride, 120 mg/d; loratadine, 10 mg/d; and placebo (lactose), twice daily. Symptoms were recorded

hourly during the study. Furthermore, all the patients completed the Japanese version of the Rhinoconjunctivitis Quality of Life Questionnaire before and after the trial. Self-evaluated symptom scores in all 3 active treatment groups showed significant improvements compared with the placebo group. Furthermore, the cetirizine group showed significant improvement in the domains of frequency of nose blowing and nasal obstruction compared with placebo. In addition, improvement in Japanese Rhinoconjunctivitis Quality of Life Questionnaire scores was higher in the cetirizine group than in the loratadine and placebo groups. Cetirizine seems to be more effective than fexofenadine and loratadine at reducing subjective symptoms in this study population.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:219717 CAPLUS
DOCUMENT NUMBER: 142:266844
TITLE: Orodispersible tablets containing fexofenadine
INVENTOR(S): Faham, Amina; Marechal, Dominique; Chenevier, Philippe
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S. Ser. No. 995,975.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005053654	A1	20050310	US 2004-495007	20041025
US 2003099700	A1	20030529	US 2001-995975	20011116
US 6723348	B2	20040420		
WO 2003041683	A2	20030522	WO 2002-EP14917	20021114
WO 2003041683	A3	20030828		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-995975 A2 20011116
WO 2002-EP14917 W 20021114

AB Orodispersible tablets disintegrate in the buccal cavity upon contact with saliva by the formation of an easy-to-swallow suspension, in <60 s, preferably in <40 s, containing fexofenadine in coated granules, and a mixture of excipients. The formulation also comprises at least 1 disintegrant, a soluble diluent, a lubricant and optionally a swelling agent, sweeteners, flavoring agents and colors; the process for obtaining such orodispersible tablets and the coated granules incorporated therein and the use of the orodispersible tablets in the treatment of seasonal allergic rhinitis. Thus, 500 g fexofenadine-HCl was mixed with 15 g Syloid FP244 and granulated with a mixture of Eudragit EPO/Eudragit NE30D in water at 16%.

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:136558 CAPLUS
DOCUMENT NUMBER: 142:225793
TITLE: A process for preparing fexofenadine composition
INVENTOR(S): Nandi, Indranil; Patel, Ashish Anilbhai; Sadatrezaei, Mohsen; Davila, Pablo; Khanapure, Virendra Maheshappa;

Durugkar, Surendra Wasudeorao
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013987	A1	20050217	WO 2004-EP8600	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005065183	A1	20050324	US 2003-631874	20030731
AU 2004262914	A1	20050217	AU 2004-262914	20040730
EP 1651218	A1	20060503	EP 2004-763678	20040730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.: US 2003-631874 A 20030731
WO 2004-EP8600 W 20040730

AB A pharmaceutical composition comprising fexofenadine or a pharmaceutically acceptable salt thereof, lactose, a low-substituted hydroxypropyl cellulose and optionally other excipients is disclosed. The fexofenadine compns. of the invention exhibit improved bioavailability as expressed as Cmax, the maximum amount of active ingredient found in the plasma, or as AUC, the area under the plasma concentration time curve. For example, a fexofenadine tablet composition was prepared by wet granulation of a powder blend containing fexofenadine-HCl 180 g, lactose 348 g, and hydroxypropyl cellulose 30 g. Wet granules were dried and then passed through 20 mesh, blended with crospovidone 36 g, and then with magnesium stearate 6 g. The lubricated granules were then compressed into tablets. The compressed tablets were optionally film coated with a composition containing HPMC 70%, TiO2 19.2%, propylene glycol 10%, yellow iron oxide 0.5%, and red iron oxide 0.3% to a total weight of 618 mg.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:396696 CAPLUS
DOCUMENT NUMBER: 138:390960
TITLE: Orodispersible tablets containing fexofenadine
INVENTOR(S): Faham, Amina; Marechal, Dominique; Chenevier, Philippe
PATENT ASSIGNEE(S): Ethypharm, Fr.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003041683	A2	20030522	WO 2002-EP14917		20021114
WO 2003041683	A3	20030828			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2003099700	A1	20030529	US 2001-995975		20011116
US 6723348	B2	20040420			
CA 2466580	AA	20030522	CA 2002-2466580		20021114
EP 1458387	A2	20040922	EP 2002-803040		20021114
EP 1458387	B1	20060809			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
CN 1592622	A	20050309	CN 2002-822602		20021114
JP 2005513008	T2	20050512	JP 2003-543570		20021114
US 2005053654	A1	20050310	US 2004-495007		20041025
PRIORITY APPLN. INFO.:			US 2001-995975	A	20011116
			WO 2002-EP14917	W	20021114

AB The present invention concerns orodispersible tablets, which are able to disintegrate in the buccal cavity upon contact with saliva by formation of an easy-to-swallow suspension, in less than 60 s, preferably in less than 40 s, containing fexofenadine in the form of coated granules, and a mixture of excipients comprising at least one disintegrating agent, a soluble diluent agent, a lubricant and optionally a swelling agent, a permeabilizing agent, sweeteners, flavoring agents and colors; the process for obtaining such orodispersible tablets and the coated granules incorporated therein and the use of said orodispersible tablets in the treatment of seasonal allergic rhinitis. Granules were prepared containing fexofenadine-HCl, Syloid FP 244, Eudragit EPO and Eudragit NE30 D. The granules were coated with a mixture of Eudragit EPO/Eudragit NE30D (50:50) and the dissoln. rates of the coated granules were determined

L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2001:833069 CAPLUS
DOCUMENT NUMBER:	135:376743
TITLE:	Packaging regimen of pseudoephedrine and fexofenadine
INVENTOR(S):	Randall, Douglas E.; Nicholas, James M.
PATENT ASSIGNEE(S):	Aventis Pharmaceuticals Inc., USA
SOURCE:	PCT Int. Appl., 27 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085148	A2	20011115	WO 2001-US14353	20010503
WO 2001085148	A3	20020801		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

AU 2001061165	A5	20011120	AU 2001-61165		20010503
US 2002022639	A1	20020221	US 2001-848463		20010503
JP 2003532671	T2	20031105	JP 2001-581802		20010503
PRIORITY APPLN. INFO.:			US 2000-202323P	P	20000505
			GB 2000-30802	A	20001218
			WO 2001-US14353	W	20010503

AB A package for dispensing 2 or more drugs is described and claimed. In one of the embodiments of this invention, the package dispenses essentially: a container to dispense drug (A) having therapeutically effective amts. of fexofenadine or its salt; and a container to dispense drug (B) containing a combination of fexofenadine and pseudoephedrine or their salts. Various preferred embodiments of the package of this invention are also described and claimed. Thus, the package of a bilayer tablet comprises a first discrete zone containing 25-33% pseudoephedrine, and a a first carrier base material. The first carrier base material comprises a mixture of carnauba wax 66-74% and a suitable antiadherent 0.50-1.50 by weight of pseudoephedrine.

L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2001:228702 CAPLUS
DOCUMENT NUMBER:	134:242705
TITLE:	Preparation of controlled drug delivery system containing pseudoephedrine and a long acting antihistamine
INVENTOR(S):	Jain, Girish Kumar; Rampal, Ashok; Sen, Himadri
PATENT ASSIGNEE(S):	Ranbaxy Laboratories Limited, India
SOURCE:	PCT Int. Appl., 27 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021168	A1	20010329	WO 2000-IB1315	20000918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6267986	B1	20010731	US 1999-405643	19990924
EP 1217997	A1	20020703	EP 2000-958919	20000918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.:	US 1999-405643	A	19990924
	WO 2000-IB1315	W	20000918

AB This invention relates to a process for the preparation of a controlled release pharmaceutical composition comprising 2 discrete zones wherein the first discrete zone comprises therapeutically effective amount of pseudoephedrine or its pharmaceutically acceptable salt as active ingredient and the second discrete zone comprises a therapeutically effective amount of a long-acting antihistamine selected from the group consisting of loratadine, azatadine, fexofenadine, terfenadine, cetirizine, astemizole, and levocabastine, or their pharmaceutically acceptable salt as active ingredient. Thus, the first tablet layer was formed from pseudoephedrine sulfate 40.00, Keltrol TF 33.33, Keltone HVCR 13.33, CaCO3 8.83, Mg stearate 1.00, and Aerosil-200 1.00%. The second tablet layer was obtained from loratadine 5.00, lactose 47.50, Avicel PH-101 33.25, FD&C-10 0.50, corn starch 10.00, starch (for paste) 3.00, and Mg

stearate 0.75% by weight The 2 layers were compressed into tablets.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 8 MEDLINE on STN
ACCESSION NUMBER: 2005238475 MEDLINE
DOCUMENT NUMBER: PubMed ID: 15875527
TITLE: The efficacy of short-term administration of 3 antihistamines vs placebo under natural exposure to Japanese cedar pollen.
AUTHOR: Hyo Sawako; Fujieda Shigeharu; Kawada Ryo; Kitazawa Shikifumi; Takenaka Hiroshi
CORPORATE SOURCE: Department of Otorhinolaryngology, Osaka Medical College, Osaka, Japan.. oto039@poh.osaka-med.ac.jp
SOURCE: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, (2005 Apr) Vol. 94, No. 4, pp. 457-64. Journal code: 9503580.. ISSN: 1081-1206.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CLINICAL TRIAL) Journal; Article; (JOURNAL ARTICLE) (RANDOMIZED CONTROLLED TRIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200505
ENTRY DATE: Entered STN: 10 May 2005 Last Updated on STN: 25 May 2005 Entered Medline: 24 May 2005

AB BACKGROUND: Japanese cedar pollinosis, a common disease with morbidity of approximately 20% in the Japanese population, is characterized by subjectively irritating symptoms during an annual 3-month period. OBJECTIVE: To investigate the effectiveness of cetirizine hydrochloride, loratadine, and fexofenadine hydrochloride in reducing pollinosis symptoms induced while walking in a park during the pollen season. METHODS: A randomized, double-masked, placebo-controlled trial was conducted in 113 individuals with Japanese cedar pollinosis during 2 days in March 2003 in Osaka Expo Park, Osaka, Japan. Participants (aged 20-57 years) were divided into 4 groups according to treatment assignment: cetirizine hydrochloride, 10 mg/d; fexofenadine hydrochloride, 120 mg/d; loratadine, 10 mg/d; and placebo (lactose), twice daily. Symptoms were recorded hourly during the study. Furthermore, all the patients completed the Japanese version of the Rhinoconjunctivitis Quality of Life Questionnaire before and after the trial. RESULTS: Self-evaluated symptom scores in all 3 active treatment groups showed significant improvements compared with the placebo group. Furthermore, the cetirizine group showed significant improvement in the domains of frequency of nose blowing and nasal obstruction compared with placebo. In addition, improvement in Japanese Rhinoconjunctivitis Quality of Life Questionnaire scores was higher in the cetirizine group than in the loratadine and placebo groups. CONCLUSION: Cetirizine seems to be more effective than fexofenadine and loratadine at reducing subjective symptoms in this study population.

L5 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:219717 CAPLUS
DOCUMENT NUMBER: 142:266844
TITLE: Orodispersible tablets containing fexofenadine
INVENTOR(S): Faham, Amina; Marechal, Dominique; Chenevier, Philippe
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S. Ser. No. 995,975.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005053654	A1	20050310	US 2004-495007	20041025
US 2003099700	A1	20030529	US 2001-995975	20011116
US 6723348	B2	20040420		
WO 2003041683	A2	20030522	WO 2002-EP14917	20021114
WO 2003041683	A3	20030828		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-995975 A2 20011116
WO 2002-EP14917 W 20021114

AB Orodispersible tablets disintegrate in the buccal cavity upon contact with saliva by the formation of an easy-to-swallow suspension, in <60 s, preferably in <40 s, containing fexofenadine in coated granules, and a mixture of excipients. The formulation also comprises at least 1 disintegrant, a soluble diluent, a lubricant and optionally a swelling agent, sweeteners, flavoring agents and colors; the process for obtaining such orodispersible tablets and the coated granules incorporated therein and the use of the orodispersible tablets in the treatment of seasonal allergic rhinitis. Thus, 500 g fexofenadine-HCl was mixed with 15 g Syloid FP244 and granulated with a mixture of Eudragit EPO/Eudragit NE30D in water at 16%.

L5 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:136558 CAPLUS
DOCUMENT NUMBER: 142:225793
TITLE: A process for preparing fexofenadine composition
INVENTOR(S): Nandi, Indranil; Patel, Ashish Anilbhai; Sadatrezaei, Mohsen; Davila, Pablo; Khanapure, Virendra Maheshappa; Durugkar, Surendra Wasudeorao
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013987	A1	20050217	WO 2004-EP8600	20040730

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005065183	A1	20050324	US 2003-631874	20030731
AU 2004262914	A1	20050217	AU 2004-262914	20040730
EP 1651218	A1	20060503	EP 2004-763678	20040730

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR

PRIORITY APPLN. INFO.: US 2003-631874 A 20030731
WO 2004-EP8600 W 20040730

AB A pharmaceutical composition comprising fexofenadine or a pharmaceutically acceptable salt thereof, lactose, a low-substituted hydroxypropyl cellulose and optionally other excipients is disclosed. The fexofenadine compns. of the invention exhibit improved bioavailability as expressed as Cmax, the maximum amount of active ingredient found in the plasma, or as AUC, the area under the plasma concentration time curve. For example, a fexofenadine tablet composition was prepared by wet granulation of a powder blend containing fexofenadine-HCl 180 g, lactose 348 g, and hydroxypropyl cellulose 30 g. Wet granules were dried and then passed through 20 mesh, blended with crospovidone 36 g, and then with magnesium stearate 6 g. The lubricated granules were then compressed into tablets. The compressed tablets were optionally film coated with a composition containing HPMC 70%, TiO2 19.2%, propylene glycol 10%, yellow iron oxide 0.5%, and red iron oxide 0.3% to a total weight of 618 mg.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1885 CAPLUS
DOCUMENT NUMBER: 142:79974
TITLE: Soft tablet containing high molecular weight cellulosics
INVENTOR(S): Wynn, David; Parikh, Nick
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004265373	A1	20041230	US 2003-608681	20030627
CA 2472432	AA	20041227	CA 2004-2472432	20040625
EP 1498114	A1	20050119	EP 2004-253844	20040625

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRIORITY APPLN. INFO.: US 2003-607766 A 20030627
US 2003-608681 A 20030627

AB The invention relates to an immediate-release tablet capable of being chewed or disintegrated in the oral cavity, which comprises an active ingredient having an optional taste masking coating, and a matrix comprising hydroxyalkyl cellulose having a weight average mol. weight of 60,000-

5,000,000. The tablet has exceptionally good mouth-feel and stability. Thus, a coating solution contained cellulose acetate 43, Hypromellose phthalate 53, and Polysorbate-80 4%. Ibuprofen granules were obtained in the conventional manner and were then coated with the above taste-masking solution

L5 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:993 CAPLUS
DOCUMENT NUMBER: 142:79963
TITLE: Soft tablets containing high molecular weight celluloses
INVENTOR(S): Wynn, David; Parikh, Nick
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004265372	A1	20041230	US 2003-607766	20030627
CA 2472432	AA	20041227	CA 2004-2472432	20040625
EP 1491184	A1	20041229	EP 2004-253843	20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.: US 2003-607766 A 20030627
US 2003-608681 A 20030627

AB An immediate release tablet capable of being chewed or subjected to disintegration in the oral cavity, comprises an active ingredient having an optional taste-masking coating, and a matrix comprising hydroxyalkyl cellulose having a weight average mol. weight of 60,000-5,000,000. The tablet has exceptionally good mouth-feel and stability. A coating solution was prepared by dispersing cellulose acetate 43, Hypromellose phthalate 53, and Polysorbate-80 4% in a solvent consisting of 90% acetone and 10% water under ambient conditions, so that the finished solution contained 10% of the coating materials. Ibuprofen granules prepared in the conventional way were then coated with the above taste-masking solution High weight average mol. weight hydroxyalkyl cellulose-containing tablets had significantly less of a grittiness feel in the mouth in comparison to those tablets lacking the high weight average mol. weight hydroxyalkyl cellulose.

L5 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:818264 CAPLUS
DOCUMENT NUMBER: 139:312454
TITLE: Antihistaminic-decongestant combination containing fexofenadine hydrochloride polymorphs
INVENTOR(S): Kamalakar, Talasila; Dash, Debashis; Srinivas, Irukula; Dhanorkar, Vipin Tatyasaheb; Mohan, Mailatur Sivaraman
PATENT ASSIGNEE(S): Reddy's Laboratories Ltd., India
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084510	A1	20031016	WO 2002-IB1068	20020404

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2481377	AA	20031016	CA 2002-2481377	20020404
AU 2002253425	A1	20031020	AU 2002-253425	20020404
EP 1490034	A1	20041229	EP 2002-722540	20020404

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: WO 2002-IB1068 W 20020404

AB The present invention relates to pharmaceutical compns., especially tablets, of antihistamine-decongestant combination. A novel polymorph of fexofenadine or pharmaceutically accepted salts with at least one decongestant are in the form of bilayered tablet. The preferred polymorphs are polymorph A and polymorph X of fexofenadine hydrochloride.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:717514 CAPLUS

DOCUMENT NUMBER: 139:235427

TITLE: Tasteless, directly compressible, fast-dissolving complexes and pharmaceutical formulations thereof

INVENTOR(S): Wadhwa, Hardeep

PATENT ASSIGNEE(S): India

SOURCE: U.S. Pat. Appl. Publ., 17 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003170310	A1	20030911	US 2003-383433	20030307
WO 2003075829	A2	20030918	WO 2003-IN48	20030307
WO 2003075829	A3	20041118		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW

AU 2003209673	A1	20030922	AU 2003-209673	20030307
EP 1454635	A1	20040908	EP 2004-5469	20040308

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPLN. INFO.: IN 2002-DE207 A 20020308
US 2003-383433 A 20030307
WO 2003-IN48 W 20030307

AB A tasteless, granular, directly compressible, stable, fast-dissolving complex of a bitter tasting basic drug, pharmaceutical formulations comprising the tasteless complex of the basic drug and dosage forms thereof are disclosed. The basic drug can be fexofenadine, and the complex of the basic drug can be a fexofenadine-carbomer complex. Processes for preparing, isolating and characterizing the tasteless complex of the bitter tasting basic drug and processes for producing the pharmaceutical formulations are also disclosed. Thus, tablets contained

fexofenadine-carbomer complex 100, microcryst. cellulose 157, directly compressible aspartame 10, croscarmellose sodium 9, talc 3, Mg stearate 3, flavor-mixed fruit 15, color-Sunset Yellow Lake 3 mg/tablet.

L5 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:396696 CAPLUS
DOCUMENT NUMBER: 138:390960
TITLE: Orodispersible tablets containing fexofenadine
INVENTOR(S): Faham, Amina; Marechal, Dominique; Chenevier, Philippe
PATENT ASSIGNEE(S): Ethypharm, Fr.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003041683	A2	20030522	WO 2002-EP14917	20021114
WO 2003041683	A3	20030828		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003099700	A1	20030529	US 2001-995975	20011116
US 6723348	B2	20040420		
CA 2466580	AA	20030522	CA 2002-2466580	20021114
EP 1458387	A2	20040922	EP 2002-803040	20021114
EP 1458387	B1	20060809		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1592622	A	20050309	CN 2002-822602	20021114
JP 2005513008	T2	20050512	JP 2003-543570	20021114
US 2005053654	A1	20050310	US 2004-495007	20041025

PRIORITY APPLN. INFO.: US 2001-995975 A 20011116
WO 2002-EP14917 W 20021114

AB The present invention concerns orodispersible tablets, which are able to disintegrate in the buccal cavity upon contact with saliva by formation of an easy-to-swallow suspension, in less than 60 s, preferably in less than 40 s, containing fexofenadine in the form of coated granules, and a mixture of excipients comprising at least one disintegrating agent, a soluble diluent agent, a lubricant and optionally a swelling agent, a permeabilizing agent, sweeteners, flavoring agents and colors; the process for obtaining such orodispersible tablets and the coated granules incorporated therein and the use of said orodispersible tablets in the treatment of seasonal allergic rhinitis. Granules were prepared containing fexofenadine-HCl, Syloid FP 244, Eudragit EPO and Eudragit NE30 D. The granules were coated with a mixture of Eudragit EPO/Eudragit NE30D (50:50) and the dissoln. rates of the coated granules were determined

L5 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:833069 CAPLUS
DOCUMENT NUMBER: 135:376743
TITLE: Packaging regimen of pseudoephedrine and fexofenadine
INVENTOR(S): Randall, Douglas E.; Nicholas, James M.
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., USA

SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085148	A2	20011115	WO 2001-US14353	20010503
WO 2001085148	A3	20020801		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001061165	A5	20011120	AU 2001-61165	20010503
US 2002022639	A1	20020221	US 2001-848463	20010503
JP 2003532671	T2	20031105	JP 2001-581802	20010503
PRIORITY APPLN. INFO.:			US 2000-202323P P	20000505
			GB 2000-30802 A	20001218
			WO 2001-US14353 W	20010503

AB A package for dispensing 2 or more drugs is described and claimed. In one of the embodiments of this invention, the package dispenses essentially: a container to dispense drug (A) having therapeutically effective amts. of fexofenadine or its salt; and a container to dispense drug (B) containing a combination of fexofenadine and pseudoephedrine or their salts. Various preferred embodiments of the package of this invention are also described and claimed. Thus, the package of a bilayer tablet comprises a first discrete zone containing 25-33% pseudoephedrine, and a a first carrier base material. The first carrier base material comprises a mixture of carnauba wax 66-74% and a suitable antiadherent 0.50-1.50 by weight of pseudoephedrine.

L5 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:525909 CAPLUS
DOCUMENT NUMBER: 135:111997
TITLE: Osmotic device containing pseudoephedrine and an H1 antagonist
INVENTOR(S): Faour, Joaquina; Ricci, Marcelo A.
PATENT ASSIGNEE(S): Laboratorios Phoenix U.S.A., Inc., USA
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051038	A1	20010719	WO 2001-US528	20010108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

US 2002102305	A1	20020801	US 2000-725655		20001129
US 6613357	B2	20030902			
CA 2396145	AA	20010719	CA 2001-2396145		20010108
EP 1246612	A1	20021009	EP 2001-900942		20010108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001007596	A	20021119	BR 2001-7596		20010108
PRIORITY APPLN. INFO.:			US 2000-175878P	P	20000113
			US 2000-725655	A	20001129
			WO 2001-US528	W	20010108

AB The present invention provides an osmotic device containing controlled release pseudoephedrine in the core in combination with a rapid release H1 antagonist in an external coat. A wide range of H1 antagonist antihistamines, especially fexofenadine, can be used in this device. Particular embodiments of the invention provide osmotic devices having predetd. release profiles. One embodiment of the osmotic device includes an external coat that has been spray coated rather than compression coated onto the device. The device with spray coated external core is smaller and easier to swallow than the similar device having a compression coated external coat. The device is useful for the treatment of respiratory congestion related disorders and allergy related disorders. The present devices provide PS and an H1 antagonist according to specific release profiles in combination with specific formulations. Thus, tablets contained pseudoephedrine-HCl 24.00, osmagent 7-90, diluent 30-40, binder 40-60, plasticizer 0.5-5, glidant 0.5-5, and lubricant 5-10 mg in the core, cellulose ester, plasticizer, water-soluble polymer, filler, colorant, fexofenadine-HCl in the coating formulation.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:166514 CAPLUS
DOCUMENT NUMBER: 130:213634
TITLE: Bilayer tablets containing decongestants and piperidinoalkanol antihistamines
INVENTOR(S): MacLaren, David D.; Lefler, John R.; Minish, Sharon K.
PATENT ASSIGNEE(S): Hoechst Marion Roussel, Inc., USA
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909957	A1	19990304	WO 1998-US15237	19980721
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9885820	A1	19990316	AU 1998-85820	19980721
AU 725811	B2	20001019		
EP 998272	A1	20000510	EP 1998-937010	19980721
EP 998272	B1	20030502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200000517	T2	20000821	TR 2000-200000517	19980721
BR 9812001	A	20000926	BR 1998-12001	19980721
EE 200000098	A	20001215	EE 2000-98	19980721

EE 4294	B1	20040615			
NZ 501248	A	20010629	NZ 1998-501248		19980721
JP 2002511102	T2	20020409	JP 1999-514300		19980721
AT 238773	E	20030515	AT 1998-937010		19980721
RU 2207879	C2	20030710	RU 1999-125326		19980721
PT 998272	T	20030930	PT 1998-937010		19980721
ES 2192781	T3	20031016	ES 1998-937010		19980721
SK 283803	B6	20040203	SK 1999-1777		19980721
IL 133420	A1	20040725	IL 1998-133420		19980721
CZ 295461	B6	20050817	CZ 1999-4581		19980721
ZA 9807552	A	19990226	ZA 1998-7552		19980820
TW 570812	B	20040111	TW 1998-87113848		19980821
MX 9911699	A	20000531	MX 1999-11699		19991214
NO 2000000932	A	20000418	NO 2000-932		20000225
NO 318246	B1	20050221			
HK 1025904	A1	20030905	HK 2000-105074		20000815
PRIORITY APPLN. INFO.:			US 1997-920158	A	19970826
			WO 1998-US15237	W	19980721

AB The present invention provides a pharmaceutical composition in the form of a bilayer tablet comprising: (a) a 1st discrete zone made with formulation which comprises a sympathomimetic drug or a salt thereof and a 1st carrier base comprising a mixture of carnauba wax and an antiadherent; wherein the 1st carrier base material provides a sustained-release of the sympathomimetic drug; and (b) a 2nd discrete zone made with formulation which comprises a piperidinoalkanol or a salt thereof and a 2nd carrier base material which contains a mixture of cellulose, pregelatinized starch, disintegrants, and lubricants; wherein the 2nd carrier base material provides an immediate release of the piperidinoalkanol. A bilayer tablet coated with Opadry YS 1-7006 contained (a) a sustained-release layer containing pseudoephedrine·HCl 120, carnauba wax 300, stearic acid flakes 4.899, colloidal SiO2 1.065 mg and (b) an immediate-release layer containing fexofenadine ·HCl 60, Avicel PH101 26, pregelatinized starch 60, Avicel PH102 190.5, croscarmellose Na 12, and Mg stearate 2.633 mg. The bilayer tablets exhibited sufficient phys. strength, content uniformity, and dissoln. profile.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT